Glizamide PM 60 Tablet contains Gliclazide 60mg, Pioglitazone 15mg, and Metformin 500mg, providing a powerful triple-action therapy for managing type-2 diabetes mellitus. This formulation is ideal for patients who require comprehensive glycemic control with enhanced insulin secretion and improved insulin sensitivity.
Gliclazide stimulates pancreatic insulin production, Pioglitazone improves peripheral insulin response, and Metformin reduces hepatic glucose output. The combination delivers balanced control of both fasting and postprandial blood sugar levels, supporting long-term metabolic stability.
This triple-combination tablet is particularly suitable for patients inadequately controlled by dual therapy or monotherapy, offering proven efficacy, convenience, and safety in a single oral dosage. It is widely used in outpatient and hospital-based diabetes management.
Adding Glizamide PM 60 Tablet to your diabetes and metabolic-care portfolio enhances your product offerings, creating strong opportunities in hospital supply, retail pharmacies, institutional procurement, export markets, and third-party manufacturing. Its clinical relevance ensures continuous demand and robust commercial performance.